KOREA WHO
-
-
-
CEO of IMBDx
Kim Tae-you
Former Seoul Med Professor Transforming Cancer Care with Liquid Biopsy
-
Last Updated on Jan 13, 2026
-
CEO of IMBDx
Life Summary
Kim Tae-you is the CEO of IMBDx.
He aims to transform the paradigm of cancer diagnosis and treatment through liquid biopsy-based precision medicine.
He was born on January 28, 1961.
He graduated from the College of Medicine at Seoul National University and earned both a master’s degree and a doctoral degree in medicine from Seoul National University Graduate School.
He completed his internship and residency at Seoul National University Hospital and worked as a clinical fellow in hematology-oncology. He later moved to the Korea Cancer Center Hospital, where he served as head of the Department of Hematology-Oncology.
After working as a researcher at the Dana-Farber Cancer Institute at Harvard Medical School in the United States, he was appointed as a professor in the Department of Internal Medicine at Seoul National University College of Medicine.
While serving as a professor at Seoul National University Graduate School of Convergence Science and Technology, he co-founded IMBDx in 2018 with Bang Doo-hee, a professor in the Department of Chemistry at Yonsei University.
He served as director of Seoul National University Cancer Hospital, president of the Korean Society for Genomics, and chairman of the board of the Korean Cancer Association.
From 2026, he presented a vision to accelerate entry into the global market and lead global standards beyond becoming the No. 1 company in the domestic liquid biopsy market.
He is an expert in the field of cancer precision medicine.
#KimTae-you #IMBDx #liquidbiopsy #precisionmedicine #cancerdiagnosis #oncology #genomics #biotechnology #globalhealthcare #medicalinnovation
He aims to transform the paradigm of cancer diagnosis and treatment through liquid biopsy-based precision medicine.
He was born on January 28, 1961.
He graduated from the College of Medicine at Seoul National University and earned both a master’s degree and a doctoral degree in medicine from Seoul National University Graduate School.
He completed his internship and residency at Seoul National University Hospital and worked as a clinical fellow in hematology-oncology. He later moved to the Korea Cancer Center Hospital, where he served as head of the Department of Hematology-Oncology.
After working as a researcher at the Dana-Farber Cancer Institute at Harvard Medical School in the United States, he was appointed as a professor in the Department of Internal Medicine at Seoul National University College of Medicine.
While serving as a professor at Seoul National University Graduate School of Convergence Science and Technology, he co-founded IMBDx in 2018 with Bang Doo-hee, a professor in the Department of Chemistry at Yonsei University.
He served as director of Seoul National University Cancer Hospital, president of the Korean Society for Genomics, and chairman of the board of the Korean Cancer Association.
From 2026, he presented a vision to accelerate entry into the global market and lead global standards beyond becoming the No. 1 company in the domestic liquid biopsy market.
He is an expert in the field of cancer precision medicine.
#KimTae-you #IMBDx #liquidbiopsy #precisionmedicine #cancerdiagnosis #oncology #genomics #biotechnology #globalhealthcare #medicalinnovation